Abstract
Background
Risk factors, early diagnosis and treatment for colorectal cancer (CRC) vary, and results in differences in incidence and outcomes across societies. To assess the influence of early diagnosis, we compare survival after CRC in a screened vs an unscreened population.
Methods
Relative survival (RS) analyses were performed to assess differences in outcomes for all CRC patients diagnosed in US SEER (2004, N=9349) and Norway (2004-05, N=8318). 39% died within three years.
Results
Stage distributions at diagnosis were different in US vs Norway (42% vs 22% localized; 35% vs 48% regional; 19% vs 23% distant). No (13%), minor (16%) or large (71%) resection rates were similar, but age and stage dependent. Overall 3-year RS was 72% in US and 67% in Norway. In multivariate models of age, sex, stage, and treatment, a weak country-effect was observed (excess mortality ratio (EMR) 0.9, CI 0.9-1.0), indicating better survival in the US, but this was significant for the youngest patients only (EMR 0.9, CI 0.8-0.9) for whom screening is an option.
Conclusion
The advantageous RS observed for US patients, and particularly for patients <80 years, likely reflects the earlier stage distribution, perhaps explained by different CRC screening practices as the US recommends screening whereas Norway does not.
Risk factors, early diagnosis and treatment for colorectal cancer (CRC) vary, and results in differences in incidence and outcomes across societies. To assess the influence of early diagnosis, we compare survival after CRC in a screened vs an unscreened population.
Methods
Relative survival (RS) analyses were performed to assess differences in outcomes for all CRC patients diagnosed in US SEER (2004, N=9349) and Norway (2004-05, N=8318). 39% died within three years.
Results
Stage distributions at diagnosis were different in US vs Norway (42% vs 22% localized; 35% vs 48% regional; 19% vs 23% distant). No (13%), minor (16%) or large (71%) resection rates were similar, but age and stage dependent. Overall 3-year RS was 72% in US and 67% in Norway. In multivariate models of age, sex, stage, and treatment, a weak country-effect was observed (excess mortality ratio (EMR) 0.9, CI 0.9-1.0), indicating better survival in the US, but this was significant for the youngest patients only (EMR 0.9, CI 0.8-0.9) for whom screening is an option.
Conclusion
The advantageous RS observed for US patients, and particularly for patients <80 years, likely reflects the earlier stage distribution, perhaps explained by different CRC screening practices as the US recommends screening whereas Norway does not.
confirm funding
Event ID
17
Session
Paper presenter
54 082
Type of Submissions
Regular session presentation, if not selected I agree to present my paper as a poster
Language of Presentation
English
First Choice History
Initial First Choice
Initial Second Choice
Weight in Programme
1 000
Status in Programme
1